Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
FierceBiotech1d
Boston Scientific posts 177% EP growth, pauses Farapulse study in first-line afib
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...
medtechdive1d
Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...
MassDevice1d
Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...
Boston Scientific Faces Trial Setback, But This Game-Changing Growth Surge Could Ignite the Stock
Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...
MassDevice6d
Boston Scientific wins FDA nods for nav-enabled Farapulse catheter, software
Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...
GlobalData on MSN3d
FDA greenlights add-ons for Boston Scientific’s Farapulse field ablation system
The Farawave NAV ablation catheter and the Faraview software are used with the Farapulse field ablation system to provide ...
Boston Scientific’s Robust Performance and Growth Prospects Drive Buy Rating
William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...